Elranatamab

Synonyms

Elranatamab, Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135, B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135, BCMA x CD3 Bispecific Antibody PF-06863135, BCMA-CD3 Bispecific Ab PF-06863135, ELRANATAMAB, PF 06863135, PF-06863135, PF06863135, RN 613, RN-613, RN613

Thesaurus

A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Elranatamab, Pharmacologic Substance

• NCI Thesaurus (external)

C181114.

This concise article on Elranatamab incorporates public domain text from the US National Library of Medicine.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.